文献速递肿瘤 PET/CT

代谢活跃肿瘤体积与总病灶糖酵解作为18F-FDG PET/CT预后生物标志物在化疗难治性转移性结直肠癌中的验证

Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
PubMed 文献 · J Nucl Med · 2018-06-29

本研究在238例来自两项前瞻性多中心试验的化疗难治性转移性结直肠癌患者中,回顾性随机分为开发集(155例)和验证集(69例),验证基线全身代谢活跃肿瘤体积(WB-MATV)和总病灶糖酵解(WB-TLG)的预后价值。WB-MATV和WB-TLG预测总生存的最优截断值分别为100 cm³和500 g。验证集中,高WB-MATV组中位OS为5.2个月 vs 低WB-MATV组12.8个月(HR 3.12,P<0.001),高WB-TLG组4.7个月 vs 低WB-TLG组13.9个月(HR 3.67,P<0.001)。多因素分析显示两者均为独立负面预后因素,预后权重高于常用临床因素。

要点

  • WB-MATV和WB-TLG预测OS的最优截断值分别为100 cm³和500 g。
  • 验证集中高WB-MATV组中位OS 5.2个月 vs 低WB-MATV组12.8个月(HR 3.12,P<0.001)。
  • 高WB-TLG组中位OS 4.7个月 vs 低WB-TLG组13.9个月(HR 3.67,P<0.001)。

核心结论

  • 基线WB-MATV和WB-TLG参数在大型化疗难治性mCRC接受MKI治疗队列中被验证为强预后指标。
  • 这些参数被确定为独立预后影像生物标志物,在常用临床因素中预后价值最高。
  • 作者认为这些生物标志物应被用于支持最佳治疗策略。

研究设计与样本

  • 从两项 successively 前瞻性多中心试验中 pooled 238例接受MKI治疗的化疗难治性mCRC患者,其中224例适合分析。
  • 患者被回顾性随机分配至开发集(n=155)和验证集(n=69)。
  • WB-MATV和WB-TLG预测OS的最优截断值通过Contal和O'Quigley方法确定。
  • 进行单因素分析评估WB-MATV和WB-TLG的预后价值,多因素分析联合临床因素识别OS的独立预后因素。
  • 各参数的预后权重通过Cox模型获得。

主要发现

  • WB-MATV和WB-TLG预测OS的最优截断值分别为100 cm³和500 g。
  • 单因素分析显示WB-MATV和WB-TLG参数在开发集和验证集中均与结局强相关。
  • 验证集中,高WB-MATV组中位OS为5.2个月 vs 低WB-MATV组12.8个月(HR 3.12,P<0.001)。
  • 验证集中,高WB-TLG组中位OS为4.7个月 vs 低WB-TLG组13.9个月(HR 3.67,P<0.001)。
  • 多因素分析确定高WB-MATV和高WB-TLG均为OS的独立负面预后参数,在已知临床预后因素中预后权重最高(HR分别为2.46和2.23,P<0.001)。

关键数值与推荐

  • WB-MATV预测OS的最优截断值为100 cm³。
  • WB-TLG预测OS的最优截断值为500 g。
  • 验证集中高WB-MATV组中位OS 5.2个月 vs 低WB-MATV组12.8个月(HR 3.12,P<0.001)。
  • 验证集中高WB-TLG组中位OS 4.7个月 vs 低WB-TLG组13.9个月(HR 3.67,P<0.001)。
  • 多因素分析中WB-MATV的HR为2.46(P<0.001),WB-TLG的HR为2.23(P<0.001)。

临床怎么用

  • 作者认为这些生物标志物应被用于支持最佳治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to validate the prognostic value of baseline whole-body metabolic active tumor volume (WB-MATV) and total lesion glycolysis (WB-TLG) measured with [18F]fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) in a large cohort of chemorefractory metastatic colorectal cancer (mCRC) patients treated with multikinase inhibitors (MKI). The secondary objective of this study was to compare WB-MATV and WB-TLG respective prognostic values to commonly used clinical prognostic factors. Methods: Out of 238 patients pooled from two successive prospective multicenter trials investigating MKI in chemorefractory mCRC, 224 were considered suitable for analysis. The patients were retrospectively randomly assigned to a development set (n = 155 patients) and a validation set (n = 69 patients). WB-MATV and WB-TLG optimal cutoffs for prediction of overall survival (OS) were determined by Contal and O'Quigley's method. Univariate analyses were performed to assess the prognostic values of WB-MATV and WB-TLG. Multivariate analyses were performed for WB-MATV and WB-TLG along with clinical factors to identify the independent prognostic factors of OS. The prognostic weight for each parameter was obtained from the Cox's model. Results: WB-MATV and WB-TLG optimal cutoffs for OS prediction were 100 cm3 and 500 g, respectively. Univariate analyses showed that WB-MATV and WB-TLG parameters were strongly related to outcome in both the development and validation sets. In the validation set, the median OS was 5.2 months vs 12.8 months for high vs low WB-MATV (HR: 3.12, P < 0.001), and 4.7 months vs 13.9 months for high vs low WB-TLG (HR: 3.67, P < 0.001). The multivariate analyses identified that both high WB-MATV and WB-TLG were independent negative prognostic parameters for OS, with the highest prognostic weight among the well-known clinical prognostic factors (HR: 2.46 and 2.23, respectively, P < 0.001). Conclusion: Baseline WB-MATV and WB-TLG parameters were validated as strong prognosticators of outcome in a large cohort of chemorefractory mCRC patients treated with MKI. These parameters were identified as independent prognostic imaging biomarkers with the highest prognostic values among the commonly used clinical factors. These biomarkers should therefore be used to support the optimal therapeutic strategy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Woff E, Hendlisz A, Ameye L, et al. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer. J Nucl Med. 2018. PMID: 29959212. doi:10.2967/jnumed.118.210161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。